Title:New Imidazo[1,2-a]pyridin-2-yl Derivatives as AChE, BChE, and LOX
Inhibitors; Design, Synthesis, and Biological Evaluation
Volume: 20
Issue: 11
Author(s): Roghayeh Esfandiari, Parsa Moghimi-Rad, Mohammed Hussen Bule, Effat Souri, Hamid Nadri, Mohammad Mahdavi, Roshanak Ghobadian and Mohsen Amini*
Affiliation:
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran14176, Iran
- The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
Keywords:
Imidazopyridine, synthesis, cholinesterase, lipoxygenase, docking study, alzheimer.
Abstract:
Background: Inhibition of cholinesterase enzyme has been recognized as an important target
in the symptomatic treatment of Alzheimer’s disease.
Objective: In the current work, a series of new N-(4-(imidazo[1,2-a]pyridin-2-yl)phenyl)cinnamamide
derivatives were synthesized and their inhibitory activities against acetyl cholinesterase, butrylcholinesterase,
and Lipoxygenase were evaluated.
Methods: The target compounds were synthesized as the literature reported with some modifications. The
AChE, BChE, and LOX inhibitory activities of the synthesized compounds were evaluated using in vitro
methods. The docking and kinetic studies were performed for the most potent compounds to evaluate the
inhibition mechanism.
Results: The structural elucidation of the synthesized imidazo-pyridine derivatives was performed by
different spectroscopic techniques including IR, NMR, and Mass. Most of the synthesized compounds
demonstrated good AChE, BChE, and LOX inhibitory activities. The most active AChE, BChE, and
sLOX-1 inhibitors were found for compounds 4a, 4g, and 4l, respectively. The docking study also revealed
that the three compounds, 4a, 4g, and 4l, have important binding interactions with the AChE,
BChE, and sLOX-1 enzyme active sites, respectively.
Conclusion: The results of current study shows imidazo[1,2-a]pyridine derivatives have potential for
development of novel drug candidate for AD as AChE, BChE and sLOX-1 inhibitors.